share_log

HC Wainwright & Co. Reiterates Buy on BELLUS Health, Maintains $20 Price Target

Benzinga ·  Mar 22, 2023 18:10

HC Wainwright & Co. analyst Andrew Fein reiterates BELLUS Health (NASDAQ:BLU) with a Buy and maintains $20 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment